Table 1 Patients characteristics and dosimetric parameters
Arm 1 | Arm 2 | |
|---|---|---|
N | 57 | 67 |
Age (years) | ||
Median (range) | 64 (51–75) | 66 (50–76) |
Gleason score | ||
≤7 | 49 (86%) | 64 (95%) |
>7 | 8 (14%) | 3 (5%) |
cT-stage | ||
<T2c | 11 (19%) | 12 (18%) |
≥T2c | 46 (81%) | 55 (82%) |
iPSA | ||
≤20 ng/ml | 40 (70%) | 57 (85%) |
>20 ng/ml | 17 (30%) | 10 (15%) |
PTV volume | ||
PTVP ± SE (cc) | 116 ± 35 | 116 ± 31 |
PTVSV ± SE (cc) | 92 ± 25 | 92 ± 17 |
PTVLN ± SE (cc) | 608 ± 89 | 613 ± 102 |
Bladder | ||
Total volume ± SE (cc) | 139 ± 94 | 125 ± 60 |
V52.6% ± SE (cc) | 101 ± 54 | 113 ± 51 |
V65.8% ± SE (cc) | 71 ± 35 | 79 ± 30 |
V78.9% ± SE (cc) | 47 ± 20 | 51 ± 19 |
V92% ± SE (cc) | 31 ± 12 | 34 ± 13 |
V100% ± SE (cc)* | 16 ± 8 | 20 ± 12 |
Rectum | ||
Total volume ± SE (cc) | 70 ± 16 | 69 ± 17 |
V52.6% ± SE (cc)* | 43 ± 12 | 54 ± 15 |
V65.8% ± SE (cc)* | 30 ± 10 | 37 ± 12 |
V78.9% ± SE (cc)* | 21 ± 7 | 24 ± 9 |
V92% ± SE (cc) | 14 ± 5 | 15 ± 6 |
V100% ± SE (cc)* | 4 ± 4 | 7 ± 5 |